# Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

> **NCT00884767** · PHASE2 · UNKNOWN · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 206 (estimated)

## Conditions studied

- Chemotherapeutic Agent Toxicity
- Colorectal Cancer
- Neurotoxicity

## Interventions

- **DRUG:** FOLFOX regimen
- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin
- **GENETIC:** gene expression analysis
- **GENETIC:** protein expression analysis
- **GENETIC:** proteomic profiling
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacogenomic studies

## Key facts

- **NCT ID:** NCT00884767
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-09
- **Primary completion:** 2009-08
- **Final completion:** —
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2009-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884767, "Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00884767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*